Breast cancer Cancer Malignant neoplasm of breast
Conditions
Interventions
1. Regimen A: Chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) repeated every four weeks for six courses, unless there is earlier progression, plus oral trimethoprim-sulphametho
Sponsors
European Organisation for Research and Treatment of Cancer (EORTC) (Belgium)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Female patients with histologically confirmed breast cancer in the following subgroups: 1.1. T4 Nx 1.2. Any N2 or N3, M0 1.3. Clinically inflammatory breast carcinoma defined as redness over at least one-third of the breast 1.4. M0 except for ipsilateral supraclavicular nodes 2. No evidence of tumour spread other than as defined above 3. No previous surgical, systemic or radiation treatment for breast cancer, other than biopsy for confirmation of the diagnosis 4. World Health Organisation (WHO) performance status zero to two 5. Adequate renal, hepatic and haematological function 6. No previous or concomitant malignancy except adequately treated squamous or basal cell carcinoma of the skin, or adequately treated cone-biopsied in situ carcinoma of the cervix uteri 7. No significant cardiac disease
Exclusion criteria
Exclusion criteria: Does not match inlcusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Added 06/08/09: 1. Response rate 2. Survival 3. Quality of life | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed